Commonwealth of Pennsylvania Public School Empls Retrmt SYS Cuts Position in Elevance Health, Inc. $ELV

Commonwealth of Pennsylvania Public School Empls Retrmt SYS trimmed its position in Elevance Health, Inc. (NYSE:ELV) by 4.4% during the fourth quarter, HoldingsChannel.com reports. The firm owned 51,694 shares of the company’s stock after selling 2,379 shares during the quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS’s holdings in Elevance Health were worth $18,121,000 at the end of the most recent quarter.

Other large investors have also modified their holdings of the company. Physician Wealth Advisors Inc. grew its stake in shares of Elevance Health by 331.6% in the third quarter. Physician Wealth Advisors Inc. now owns 82 shares of the company’s stock valued at $26,000 after buying an additional 63 shares in the last quarter. Rossby Financial LCC grew its stake in shares of Elevance Health by 110.0% in the third quarter. Rossby Financial LCC now owns 84 shares of the company’s stock valued at $28,000 after buying an additional 44 shares in the last quarter. ORG Partners LLC grew its stake in shares of Elevance Health by 120.4% in the fourth quarter. ORG Partners LLC now owns 108 shares of the company’s stock valued at $38,000 after buying an additional 59 shares in the last quarter. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA acquired a new stake in shares of Elevance Health in the fourth quarter valued at about $38,000. Finally, Dorato Capital Management acquired a new stake in shares of Elevance Health in the fourth quarter valued at about $41,000. Institutional investors and hedge funds own 89.24% of the company’s stock.

Elevance Health Price Performance

Shares of NYSE ELV opened at $394.40 on Monday. Elevance Health, Inc. has a fifty-two week low of $273.71 and a fifty-two week high of $408.00. The business has a 50 day moving average price of $343.75 and a two-hundred day moving average price of $339.15. The company has a quick ratio of 1.48, a current ratio of 1.48 and a debt-to-equity ratio of 0.70. The firm has a market cap of $85.65 billion, a PE ratio of 16.78, a price-to-earnings-growth ratio of 2.22 and a beta of 0.67.

Elevance Health (NYSE:ELV) last issued its quarterly earnings data on Wednesday, April 22nd. The company reported $12.58 earnings per share for the quarter, beating analysts’ consensus estimates of $10.74 by $1.84. Elevance Health had a return on equity of 15.58% and a net margin of 2.62%.The firm had revenue of $49.49 billion during the quarter, compared to analyst estimates of $48.21 billion. During the same quarter last year, the firm earned $11.97 EPS. Elevance Health’s quarterly revenue was up 1.5% on a year-over-year basis. Elevance Health has set its FY 2026 guidance at 19.850- EPS. Sell-side analysts expect that Elevance Health, Inc. will post 26.94 earnings per share for the current fiscal year.

Elevance Health Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, June 25th. Shareholders of record on Wednesday, June 10th will be paid a dividend of $1.72 per share. This represents a $6.88 dividend on an annualized basis and a yield of 1.7%. The ex-dividend date is Wednesday, June 10th. Elevance Health’s dividend payout ratio (DPR) is 29.26%.

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on ELV. Sanford C. Bernstein increased their target price on Elevance Health from $384.00 to $424.00 and gave the company an “outperform” rating in a research note on Friday, April 24th. Weiss Ratings upgraded Elevance Health from a “hold (c-)” rating to a “hold (c)” rating in a research note on Monday, May 18th. JPMorgan Chase & Co. increased their target price on Elevance Health from $397.00 to $411.00 and gave the company an “overweight” rating in a research note on Tuesday, April 28th. The Goldman Sachs Group increased their target price on Elevance Health from $350.00 to $370.00 and gave the company a “neutral” rating in a research note on Friday, April 24th. Finally, Royal Bank Of Canada lowered Elevance Health from an “outperform” rating to a “sector perform” rating and set a $358.00 target price for the company. in a research note on Tuesday, February 3rd. Fourteen equities research analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $403.11.

Elevance Health Company Profile

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.